← FDA DRUG APPROVALS

FDA ANDA · ANDA076035

HALOPERIDOL

Sponsor: TEVA PHARMS USA

APPLICATION
ANDA076035
TYPE
ANDA
ORIGINAL APPROVAL
2001-08-29
LATEST ACTION
2025-01-22
ROUTE
INJECTION
DOSAGE FORM
INJECTABLE
MARKETING STATUS
Discontinued

Products

HALOPERIDOLDiscontinued
HALOPERIDOL LACTATE EQ 5MG BASE/ML · INJECTABLE · INJECTION

Approval history

2025-01-22Labeling · Supplement 27 · standardAP
2025-01-13Labeling · Supplement 26 · standardAP
2018-06-08Labeling · Supplement 24 · standardAP
2018-06-08Labeling · Supplement 23 · standardAP
2015-09-11Labeling · Supplement 21 · standardAP
2012-01-03Labeling · Supplement 14AP
2011-10-14Labeling · Supplement 6AP
2010-12-03Labeling · Supplement 9AP
2009-04-30Labeling · Supplement 4AP
2001-08-29OriginalLetterAP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industryGMP disciplineFDA drug shortagesFDA enforcement & recalls

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →